Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2019

17.09.2019 | special report

Highlights on chronic lymphocytic leukemia presented at the 2018 American Society of Hematology Meeting

verfasst von: MD Daniel Heintel

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Insights presented at the last American Society of Hematology meeting changed standards of care in the first-line treatment. In patients <70 years with unmutated CLL, ibrutinib is the new standard resulting in a survival benefit compared to FCR (fludarabine, cyclophosphamide and rituximab). There was no progression-free survival or overall survival benefit in the subgroup of mutated patients for ibrutinib-based regimens. A randomized trial again showed no benefit of rituximab when added to ibrutinib compared to ibrutinib alone. Moreover, several promising treatment strategies in the relapsed/refractory setting were presented. The combination of ibrutinib with venetoclax reduces tumor lysis syndrome risk and generates MRD (minimal residual disease) negativity.
Literatur
1.
Zurück zum Zitat Shanafelt TD, Wang V, Kay NE, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):LBA-4. Shanafelt TD, Wang V, Kay NE, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):LBA-4.
2.
Zurück zum Zitat Woyach JA, Ruppert AS, Nyla A. Heerema NA, et al. Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):6. Woyach JA, Ruppert AS, Nyla A. Heerema NA, et al. Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):6.
3.
Zurück zum Zitat Moreno C, Greil R, Demirkan F, et al. Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1): 691. Moreno C, Greil R, Demirkan F, et al. Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1): 691.
4.
Zurück zum Zitat Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):692. Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):692.
5.
Zurück zum Zitat Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4424. CrossRef Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4424. CrossRef
6.
Zurück zum Zitat Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):696. CrossRef Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):696. CrossRef
7.
Zurück zum Zitat Hillmen P, Rawstron A, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):182. CrossRef Hillmen P, Rawstron A, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):182. CrossRef
8.
Zurück zum Zitat Greil R, Fraser G, Leber B, et al. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):5548. CrossRef Greil R, Fraser G, Leber B, et al. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):5548. CrossRef
9.
Zurück zum Zitat Kater AP, Hillmen P, Eichhorst B, et al. First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):185. CrossRef Kater AP, Hillmen P, Eichhorst B, et al. First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):185. CrossRef
10.
Zurück zum Zitat Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II Study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter’s Transformation. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):297. CrossRef Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II Study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter’s Transformation. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):297. CrossRef
11.
Zurück zum Zitat Staber PB, Chanan-Khan AA, Munir T, et al. Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4433. CrossRef Staber PB, Chanan-Khan AA, Munir T, et al. Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4433. CrossRef
12.
Zurück zum Zitat Siddiqi T, Soumerai JD, Wierda WG, et al. Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from Transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):300. CrossRef Siddiqi T, Soumerai JD, Wierda WG, et al. Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from Transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):300. CrossRef
Metadaten
Titel
Highlights on chronic lymphocytic leukemia presented at the 2018 American Society of Hematology Meeting
verfasst von
MD Daniel Heintel
Publikationsdatum
17.09.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00521-y